Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K.
Tasaki Y, et al. Among authors: matsuyama n.
Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6.
Int J Urol. 2023.
PMID: 37278575